{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T22:47:38Z","timestamp":1756075658664},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.nbd.2013.09.017","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T04:02:35Z","timestamp":1380600155000},"page":"39-46","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Safety and regulatory requirements and challenge for CNS drug development"],"prefix":"10.1016","volume":"61","author":[{"given":"Shayne C.","family":"Gad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2013.09.017_bb0005","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuron.2011.05.007","article-title":"Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta Stone","volume":"70","author":"Aboody","year":"2011","journal-title":"Neuro"},{"issue":"2","key":"10.1016\/j.nbd.2013.09.017_bb0010","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/toxsci\/kfm058","article-title":"Development of safety qualification thresholds and their use in drug product evaluation","volume":"97","author":"Ball","year":"2007","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.nbd.2013.09.017_bb0015","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1124\/dmd.109.028134","article-title":"Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database","volume":"37","author":"Chico","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.nbd.2013.09.017_bb0020","unstructured":"Code of Federal Regulations; Title 21, Volume 5; (1 April 2005). 21 CFR 314.3(b); Title 21 Food and Drugs, Chapter I- Food and Drug Administration Department of Health and Human Services, Subchapter D- Drugs for Human Use. Part 314, Applications for FDA Approval to Market a New Drug, Subpart A- General Provisions, Sec. 314.3 Definitions. Revised as of 1 April 2005. Available at www.fda.gov."},{"key":"10.1016\/j.nbd.2013.09.017_bb0025","series-title":"Guidelines on the Limits of Genotoxic Impurities","author":"EMEA","year":"2004"},{"issue":"2","key":"10.1016\/j.nbd.2013.09.017_bb0030","first-page":"404","article-title":"Challenges in the search for drugs to treat central nervous system disorders","volume":"329","author":"Enna","year":"2009","journal-title":"Perspect. Pharmacol."},{"key":"10.1016\/j.nbd.2013.09.017_bb0035","series-title":"FDA Introduction to Total Drug Quality","author":"FDA","year":"1971"},{"key":"10.1016\/j.nbd.2013.09.017_bb0045","series-title":"Drug Safety Evaluation","author":"Gad","year":"2009"},{"key":"10.1016\/j.nbd.2013.09.017_bb0050","series-title":"Animal Models in Toxicology","author":"Gad","year":"2013"},{"key":"10.1016\/j.nbd.2013.09.017_bb0055","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1602\/neurorx.2.4.683","article-title":"Central nervous system drug development: an integrative biomarker approach toward individualized medicine","volume":"2","author":"Gomez-Mancilla","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.nbd.2013.09.017_bb0060","series-title":"Nonclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals","author":"Hastings","year":"2007"},{"key":"10.1016\/j.nbd.2013.09.017_bb0065","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.drugalcdep.2009.08.004","article-title":"Risk management and post-marketing surveillance of CNS drugs","volume":"105S","author":"Henningfield","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.nbd.2013.09.017_bb0070","series-title":"E8: General Considerations for Clinical Trials","author":"ICH","year":"1998"},{"key":"10.1016\/j.nbd.2013.09.017_bb0075","series-title":"Guidance for Industry, Q3A Impurities in New Drug Substances","author":"ICH","year":"2003"},{"key":"10.1016\/j.nbd.2013.09.017_bb0080","series-title":"Guidance for Industry, Q3C Impurities: Residual Solvents","author":"ICH","year":"1997"},{"key":"10.1016\/j.nbd.2013.09.017_bb0085","series-title":"Q3B(R) Impurities in New Drug Products","article-title":"Guidance for industry","author":"ICH","year":"2003"},{"key":"10.1016\/j.nbd.2013.09.017_bb0095","series-title":"M3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals","author":"ICH","year":"2008"},{"key":"10.1016\/j.nbd.2013.09.017_bb0100","series-title":"M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk","author":"ICH","year":"2013"},{"key":"10.1016\/j.nbd.2013.09.017_bb0105","series-title":"S5(R2) Detection of Toxicity to Reproduction for Medical Products & Toxicity to Male Fertility","author":"ICH","year":"2005"},{"key":"10.1016\/j.nbd.2013.09.017_bb0110","series-title":"International Conference on Harmonization: Safety Pharmacology Studies for Human Pharmaceuticals","article-title":"S7A","author":"ICH","year":"2001"},{"key":"10.1016\/j.nbd.2013.09.017_bb0115","series-title":"S2(R1) Guidance on Genotoxicity Testing and Data Interpretation for pPharmaceuticals Intended for Human Us","author":"ICH","year":"2008"},{"key":"10.1016\/j.nbd.2013.09.017_bb0120","series-title":"S3A Note for Guidance on Toxicokinetics: The Assessment of Systematic Exposure in Toxicity Studies","author":"ICH","year":"1994"},{"key":"10.1016\/j.nbd.2013.09.017_bb0125","series-title":"S6: Preclinical Safety Evaluation of Biotechnology Derived Pharmaceuticals","author":"ICH","year":"2004"},{"key":"10.1016\/j.nbd.2013.09.017_bb0130","series-title":"Drug-like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization","first-page":"122","article-title":"Blood\u2013brain barrier","author":"Kerns","year":"2008"},{"key":"10.1016\/j.nbd.2013.09.017_bb0135","series-title":"Animal Models of Cognitive Impairment","author":"Levin","year":"2006"},{"key":"10.1016\/j.nbd.2013.09.017_bb0140","series-title":"Editorial","first-page":"1","article-title":"CNS drug discovery and development: when will we rescue Tantalus?","author":"Manji","year":"2008"},{"issue":"1","key":"10.1016\/j.nbd.2013.09.017_bb0145","doi-asserted-by":"crossref","DOI":"10.1097\/01.pra.0000393844.48593.82","article-title":"CNS drug development: Part III: future directions","volume":"17","author":"Preskorn","year":"2011","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.nbd.2013.09.017_bb0150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/009286159803200140","article-title":"Labeling of drug and biologic products for pediatric use","volume":"32","author":"Schacter","year":"1998","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.nbd.2013.09.017_bb0155","series-title":"Contract Pharma","article-title":"Quality assurance and good lab practice","author":"Swidersky","year":"2007"},{"key":"10.1016\/j.nbd.2013.09.017_bb0160","series-title":"Guidance for Industry, NDAs: Impurities in Drug Substances","article-title":"Food and Drug Administration, Center for Drug Evaluation and Research (CDER)","author":"US Department of Health and Human Services","year":"2000"},{"key":"10.1016\/j.nbd.2013.09.017_bb0165","series-title":"CDER Guidelines for Industry, Safety Testing of Drug Metabolites","author":"USFDA","year":"2008"},{"key":"10.1016\/j.nbd.2013.09.017_bb0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.euroneuro.2010.09.003","article-title":"Adaptive design clinical trials and trial logistics models in CNS drug development","volume":"21","author":"Wang","year":"2011","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996113002635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996113002635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T12:43:02Z","timestamp":1564231382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996113002635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":32,"alternative-id":["S0969996113002635"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2013.09.017","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and regulatory requirements and challenge for CNS drug development","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2013.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}